Previous 10 | Next 10 |
BrainStorm Cell Therapeutics to Meet with US FDA to Discuss Development Plan for NurOwn as a Treatment of ALS PR Newswire - Path forward for ALS is a registrational Phase 3b U.S. clinical trial - - Biologics License Application to be withdrawn without prejudice - ...
2023-10-05 06:59:00 ET 3 Tips for Creating a Profitable Penny Stocks Watchlist Penny stocks offer a unique opportunity for investors looking to diversify their portfolios and potentially achieve substantial returns. These stocks, typically priced under $5, have the potential to provide ...
BrainStorm Cell Therapeutics Provides Update on FDA Advisory Committee Meeting to Review NurOwn for the Treatment of ALS PR Newswire NEW YORK , Sept. 27, 2023 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem...
2023-09-27 18:29:10 ET More on BrainStorm Cell Therapeutics Brainstorm Cell Therapeutics: I Anticipate A Positive AdCom But There Are Major Risks Brainstorm Cell Therapeutics Inc. (BCLI) Q2 2023 Earnings Call Transcript BrainStorm stock halted as FDA panel reviews AL...
2023-09-27 13:58:25 ET More on BrainStorm Cell Therapeutics Brainstorm Cell Therapeutics: I Anticipate A Positive AdCom But There Are Major Risks Brainstorm Cell Therapeutics Inc. (BCLI) Q2 2023 Earnings Call Transcript Brainstorm falls as FDA posts briefing docs on ...
BrainStorm Cell Therapeutics Stock Trading Halted Today PR Newswire FDA advisory committee (ADCOM) meeting to review NurOwn ® for ALS NEW YORK , Sept. 27, 2023 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading devel...
2023-09-25 08:45:00 ET More on BrainStorm Seeking Alpha’s Quant Rating on BrainStorm Cell Therapeutics Historical earnings data for BrainStorm Cell Therapeutics Financial information for BrainStorm Cell Therapeutics Brainstorm Cell Therapeutics: I Anti...
2023-09-22 15:00:17 ET More on the markets No Signs Of A Major Top Yet, Staying Long BofA strategists have changed their view of the S&P 500 target, up 4%. Quant stock news sentiment measure keeps improving - BofA Amazon, Disney, Boeing boosted in Wells F...
2023-09-15 18:03:07 ET Summary BCLI has completed a phase 3 trial in ALS. Despite not meeting the primary endpoint BCLI is still applying for approval and an AdCom meeting is scheduled for September 27. NurOwn was significantly better than placebo in the pre-specified subgroup of ...
2023-08-14 11:03:10 ET Brainstorm Cell Therapeutics Inc. (BCLI) Q2 2023 Earnings Conference Call August 14, 2023 8:00 AM ET Company Participants Michael Wood - LifeSci Advisors Chaim Lebovits - President and Chief Executive Officer Stacy Lindborg - Co-Chief Execu...
News, Short Squeeze, Breakout and More Instantly...
Brainstorm Cell Therapeutics Inc. Company Name:
BCLI Stock Symbol:
NASDAQ Market:
Brainstorm Cell Therapeutics Inc. Website:
BrainStorm Cell Therapeutics to Provide Corporate Mid-Year Update on NurOwn Program PR Newswire A conference call and webcast will be held Monday, July 8 , at 8:00 a.m. Eastern Time NEW YORK , July 1, 2024 /PRNewswire/ -- BrainStorm Cell Therapeut...
BrainStorm Cell Therapeutics Announces Pricing of $4.0 Million Registered Direct Offering PR Newswire NEW YORK , June 27, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) (the "Company"), a leading developer of adult stem cell therapeutics fo...
BrainStorm Cell Therapeutics Reaches Alignment with FDA on CMC Aspects of Phase 3b NurOwn® Clinical Trial PR Newswire NEW YORK , June 26, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell thera...